Andre Kalil, MD, MPH
Item
Title
Andre Kalil, MD, MPH
Description
In February 2020, Andre Kalil, MD, MPH, led a team at Nebraska Medicine in enrolling some of the first COVID-19 patients in a National Institute of Health clinical trial to study remdesivir as a treatment for the disease. The study confirmed remdesivir as an effective treatment and was approved for emergency use in May 2020. The drug received full FDA approval in October 2020 and continues to be a form of treatment for patients with severe COVID-19 conditions.
Identifier
4.12.2b.6
Rights
Courtesy of LuAnn Larson, RN, BSN, Director of Clinical Research Operations at Nebraska Medicine